|
Volumn 59, Issue 4, 2001, Pages 1592-1593
|
Platelet-derived growth factor: A new clinical target on the horizon
|
Author keywords
Anti Thy 1.1 nephritis; Glomerular disease; Mesangial cell proliferation; Platelet derived growth factors
|
Indexed keywords
6,7 DIMETHYL 2 PHENYLQUINOXALINE;
COMPLEMENTARY DNA;
IMATINIB;
KI 6896;
PLATELET DERIVED GROWTH FACTOR;
PLATELET DERIVED GROWTH FACTOR A;
PLATELET DERIVED GROWTH FACTOR ANTAGONIST;
PLATELET DERIVED GROWTH FACTOR B;
PLATELET DERIVED GROWTH FACTOR BB;
PLATELET DERIVED GROWTH FACTOR RECEPTOR;
PROTEIN TYROSINE KINASE INHIBITOR;
UNCLASSIFIED DRUG;
ADVERSE DRUG REACTION;
ANIMAL MODEL;
CELL PROLIFERATION;
CLINICAL TRIAL;
EDITORIAL;
ENZYME INHIBITION;
GLOMERULONEPHRITIS;
HUMAN;
INFLAMMATION;
KIDNEY DISEASE;
KIDNEY FIBROSIS;
MESANGIUM CELL;
MOUSE;
NONHUMAN;
PATHOGENESIS;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RAT;
TOXICITY TESTING;
|
EID: 0035070049
PISSN: 00852538
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1523-1755.2001.0590041592.x Document Type: Editorial |
Times cited : (7)
|
References (11)
|